ReviewCurrent opinion in biotechnology2020
Advances in microphysiological blood-brain barrier (BBB) models towards drug delivery.
Review in Current opinion in biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Meta-analysis of the make-up and properties of in vitro models of the healthy and diseased blood-brain barrier.Nature biomedical engineering · 2025Pooled it
- Modeling blood-brain barrier-glioblastoma interactions: implications for chemoresistance and therapeutic targeting.Fluids and barriers of the CNS · 2026Review
- Organoids in drug development: from predictive models to regulatory integration.Drug discovery today · 2026Review
- Redirecting the route: Monocyte-mediated delivery of oHSV-1 across a human BBB-on-chip model.Materials today. Bio · 2025Article
- Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery.RSC advances · 2025Review
- A human skin-on-a-chip platform for microneedling-driven skin cancer treatment.Materials today. Bio · 2025Article
- Trajectory of brain-derived amyloid beta in Alzheimer's disease: where is it coming from and where is it going?Translational neurodegeneration · 2024Review
- The neurovascular unit-on-a-chip: modeling ischemic stroke to stem cell therapy.Neural regeneration research · 2024Article
- Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives.CNS neuroscience & therapeutics · 2024Review
- Revolutionizing neurotherapeutics: blood-brain barrier-on-a-chip technologies for precise drug delivery.Annals of medicine and surgery (2012) · 2024Review
- Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer's Disease.Molecular neurobiology · 2024Review
- Advances in the Model Structure of In Vitro Vascularized Organ-on-a-Chip.Cyborg and bionic systems (Washington, D.C.) · 2024Article
- Lipid-based nanoparticles for drug delivery in Parkinson's disease.Translational neuroscience · 2024Review
- Quinoline Derivatives: Promising Antioxidants with Neuroprotective Potential.Antioxidants (Basel, Switzerland) · 2023Article
- Targeting Non-Coding RNA for CNS Injuries: Regulation of Blood-Brain Barrier Functions.Neurochemical research · 2023Review
- Functional genomics in stroke: current and future applications of iPSCs and gene editing to dissect the function of risk variants.BMC cardiovascular disorders · 2023Review
- Tissue engineering modalities in skeletal muscles: focus on angiogenesis and immunomodulation properties.Stem cell research & therapy · 2023Review
- Endothelial-Specific Targeting of RhoA Signaling via CD31 Antibody-Conjugated Nanoparticles.The Journal of pharmacology and experimental therapeutics · 2023Article
- The Impact of the Cellular Environment and Aging on Modeling Alzheimer's Disease in 3D Cell Culture Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Organ-On-A-Chip Models of the Blood-Brain Barrier: Recent Advances and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Though the blood-brain barrier (BBB) is vital for the maintenance of brain homeostasis, it also accounts for a high attrition rate of therapies targeting the central nervous system (CNS). The challenge of delivery across the BBB is attributed to a combination of low permeability through an endothelium closely knit by tight and adherens junctions, extremely low rates of endothelial transcytosis, and efflux transporters. In the past decade, enormous research efforts have been spent to develop BBB penetration strategies using biochemical or physical stimuli, aided by BBB-on-chips or microphysiological BBB models to facilitate in vitro studies. Here, we discuss recent advances in BBB-chip technology that have enabled effective preclinical screenings of brain targeting therapeutics and external stimulation, such as sonoporation and electroporation, for improved BBB penetration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.